References
- Rimola A, García-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi JM. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000;32:142–53.
- Cuarner C, Runyon BA, Young S, Heck M, Sheikh MY. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 1997;26:1372–8.
- Lee JM, Han KH, Ahn SH. Ascites and spontaneous bacterial peritonitis: an Asian perspective. J Gastroenterol Hepatol 2009;24:1494–503.
- Sánchez E, Such J, Chiva MT, Soriano G, Llovet T, Mercè J, Development of an experimental model of induced bacterial peritonitis in cirrhotic rats with or without ascites. Am J Gastroenterol 2007;102:1230–6.
- Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000;25:333–40.
- Martinsen TC, Bergh K, Waldum HL. Gastric juice: a barrier against infectious disease. Basic Clin Pharmacol Toxicol 2005;96:94–102.
- Laheij R, Sturkenboom MC, Hassing R, Dieleman J, Stricker BH, Jansen SB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955–60.
- Prod'hom G, Leuenberger P, Koerfer J, Blum A, Chiolero R, Schaller MD, Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer. A randomized controlled trial. Ann Intern Med 1994;120:653–62.
- Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, Talmor D. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010;170:784–90.
- Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294:2989–95.
- Parkman HP, Urbain JL, Knight LC, Brown KL, Trate DM, Miller MA, Effect of gastric acid suppressants on human gastric motility. Gut 1998;42:243–50.
- Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxbock F, Graninger W. Omeprazole treatment diminished intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002;30:1118–22.
- Campbell MS, Obstein K, Reddy KR, Yang YX. Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci 2008;53:394–8.
- Bajaj JS, Zadvornova Y, Heuman DM, Hafeezullah M, Hoffmann RG, Sanyal AJ, Saeian K. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009;104:1130–4.
- Bauer TM, Steinbrückner B, Brinkmann FE, Ditzen AK, Schwacha H, Aponte JJ, Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 2001;96:2962–7.
- Koulaouzidis A, Bhat S, Karagiannidis A, Tan WC, Linaker BD. Spontaneous bacterial peritonitis. Postgrad Med J 2007;83:379–83.
- Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, Bacterial overgrowth during treatment with omeprazole compared with cimetidine. Gut 1996; 39:54–9.
- Takahashi Y, Amano Y, Yuki T, Ose T, Miyake T, Kushiyama Y, Influence of acid suppressants on gastric emptying: Cross–over analysis in healthy volunteers. J Gastroenterol Hepatol 2006;21:1664–8.
- Kalaitzakis E, Björnsson E. Inadequate use of proton-pump inhibitors in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2008;20:512–18.
- Runyon BA, Cannwati HN, Akriviatis EA. Optimization of ascetic fluid culture technique. Gastroenterology 1998;95:1351–5.